ACTINIUM PHARMAC

ATNM AMEX
0.2341
-0.0046
-1.93%
Closed 16:00 07/22 EDT
Open
0.2375
Prev Close
0.2387
High
0.2500
Low
0.2341
Volume
609.06K
Avg Vol (3M)
1.20M
52 Week High
0.8651
52 Week Low
0.2300
% Turnover
0.38%
Market Cap
37.93M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers ACTINIUM PHARMAC ATNM stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Actinium Pharmaceuticals, Inc. (Actinium) is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. The Company is engaged in developing therapies for diseases using its alpha particle immunotherapy platform and other related technologies. The Company's products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131). Actimab-A is in human clinical trials stage for acute myeloid leukemia (AML) and Iomab-B in clinical trial stage for use in myeloconditioning for hematopoietic stem cells transplantation (HSCT) in various indications. Its products under development are monoclonal antibodies labeled with radioisotopes. It has four product candidates in clinical trials: Actimab-A (HuM195-Ac-225), Iomab-B (BC8-I-131), BC8-Y-90 and BC8-SA. It is pursuing development of Actimab-A and Iomab-B, while BC8-Y-90 and BC8-SA are in physician sponsored clinical phase I trials.
MORE >

Recently

Name
Price
%Change